Cartesian Therapeutics’ Descartes-08 Gains the US FDA’s Rare Pediatric Disease Designation to Treat Juvenile Dermatomyositis
Shots:
- The US FDA has granted RPDD to Descartes-08 for treating juvenile dermatomyositis (JDM). Cartesian will be eligible for a priority review voucher, if approved
- Descartes-08 is currently being assessed under P-IIb study for generalized myasthenia gravis, another P-II study for systematic lupus erythematosus as well as a P-II basket study for additional autoimmune disorders. IND for the basket study is anticipated in the YE’24 which will include juvenile SLE, juvenile MG & other conditions
- Descartes-08 is an autologous mRNA CAR T-cell therapy targeting BCMA that requires no preconditioning CT and avoids the risk of genomic integration linked to cancer formation
Ref: Cartesian Therapeutics | Image: Cartesian Therapeutics
Related Posts:- Cartesian Therapeutics’ Descartes-08 Gains the US FDA’s RMAT Designation to Treat Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
